Baseline Computed Tomography Radiomic and Genomic Assessment of Head and Neck Squamous Cell Carcinoma.
Adult
Aged
Aged, 80 and over
Class I Phosphatidylinositol 3-Kinases
/ genetics
Ephrin-A2
/ genetics
ErbB Receptors
/ genetics
Female
Gene Expression Profiling
/ methods
Gene Expression Regulation, Neoplastic
Head and Neck Neoplasms
/ diagnostic imaging
Humans
Male
Middle Aged
Precision Medicine
Radiographic Image Interpretation, Computer-Assisted
Receptor, EphA2
Receptor, Fibroblast Growth Factor, Type 1
/ genetics
Receptor, Fibroblast Growth Factor, Type 2
/ genetics
Receptor, Fibroblast Growth Factor, Type 3
/ genetics
Receptors, Fibroblast Growth Factor
/ genetics
Retrospective Studies
Squamous Cell Carcinoma of Head and Neck
/ diagnostic imaging
Tomography, X-Ray Computed
/ methods
Journal
Journal of computer assisted tomography
ISSN: 1532-3145
Titre abrégé: J Comput Assist Tomogr
Pays: United States
ID NLM: 7703942
Informations de publication
Date de publication:
Historique:
entrez:
23
7
2020
pubmed:
23
7
2020
medline:
30
7
2020
Statut:
ppublish
Résumé
To determine the relationship between computed tomography (CT) radiomic features and gene expression levels in head and neck squamous cell carcinoma (HNSCC). This retrospective study included 66 patients with HNSCC primary lesions (36 oropharyngeal, 6 hypopharyngeal, 10 laryngeal, 14 oral cavity). Gene expression information for 6 targetable genes (fibroblast growth factor receptor [FGFR]1, epidermal growth factor receptor [EGFR], FGFR2, FGFR3, EPHA2, PIK3CA) was obtained via Agilent microarrays from samples collected between 1997 and 2010. Pretreatment contrast-enhanced soft tissue neck CT scans were reviewed, and 142 radiomics features were derived. R was used to calculate Pearson correlation coefficients were calculated between gene expression levels and each radiomic feature. P values were adjusted using the false discovery rate (FDR) method. There were significant correlations between FGFR1 and 5 gray level cooccurrence matrix (GLCM) features with FDR-adjusted P values less than 0.05: inertia (r = 0.366, FDR-adjusted P = 0.006), absolute value (r = 0.31, FDR-adjusted P = 0.024), contrast (r = 0.366, FDR-adjusted P = 0.006), difference average (r = 0.31, FDR-adjusted P = 0.024), and difference variance (r = 0.37, FDR-adjusted P = 0.005). There was 1 correlated feature for FGFR2 with an FDR-adjusted P value less than 0.05: fractal dimension box-coarse (r = 0.33, FDR-adjusted P = 0.018). There was 1 correlated feature for EPHA2 with an FDR-adjusted P value less than 0.05: GLCM entropy (r = -0.28, FDR-adjusted P = 0.049). Six of the 7 features that showed significant correlation belonged to the GLCM class of features. The CT radiomic features demonstrate correlations with FGFR1 status in HNSCC and should be further investigated for their potential to predict FGFR1 status.
Identifiants
pubmed: 32697524
doi: 10.1097/RCT.0000000000001056
pii: 00004728-202007000-00013
doi:
Substances chimiques
EPHA2 protein, human
0
Ephrin-A2
0
Receptors, Fibroblast Growth Factor
0
Class I Phosphatidylinositol 3-Kinases
EC 2.7.1.137
PIK3CA protein, human
EC 2.7.1.137
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
FGFR1 protein, human
EC 2.7.10.1
FGFR2 protein, human
EC 2.7.10.1
FGFR3 protein, human
EC 2.7.10.1
Receptor, EphA2
EC 2.7.10.1
Receptor, Fibroblast Growth Factor, Type 1
EC 2.7.10.1
Receptor, Fibroblast Growth Factor, Type 2
EC 2.7.10.1
Receptor, Fibroblast Growth Factor, Type 3
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
546-552Références
Mandal R, Şenbabaoğlu Y, Desrichard A, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight. 2016;1:e89829 Published 2016 Oct 20.
American Cancer Society (2019) Cancer Facts & Figures 2019.
Calvalho A, Nishimoto I, Califano J, et al. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer. 2005;114:806–816.
SEER (2020) Cancer of the oral cavity and pharynx. Available at: https://seer.cancer.gov/statfacts/html/oralcav.html. Accessed date June 19, 2020.
Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–1127.
Mehra R, Seiwert TY, Gupta S, et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. 2018;119:153–159.
Shin SH, Bode AM, Dong Z. Precision medicine: the foundation of future cancer therapeutics. Npj precision Onc. 2017;1:1–3.
Mazurowski MA. Radiogenomics: what it is and why it is important. J Am Coll Radiol. 2015;12:862–866.
Trebeschi S, Drago SG, Birkbak NJ, et al. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. Ann Oncol. 2019;30:998–1004.
Zhang Y, Oikonomou A, Wong A, et al. Radiomics-based prognosis analysis for non- small cell lung cancer. Sci Rep. 2017;7:46349. doi:https://doi.org/10.1038/srep46349.
doi: 10.1038/srep46349
Dang M, Lysack JT, Wu T, et al. MRI texture analysis predicts p53 status in head and neck squamous cell carcinoma. AJNR Am J Neuroradiol. 2015;36:166–170.
Miller TA, Robinson KR, Li H, et al. Prognostic value of pre-treatment CT texture analysis in combination with change in size of the primary tumor in response to induction chemotherapy for HPV-positive oropharyngeal squamous cell carcinoma. Quant Imaging Med Surg. 2019;9:399–408.
Kuno H, Qureshi M, Chapman M, et al. CT texture analysis potentially predicts local failure in head and neck squamous cell carcinoma treated with chemoradiotherapy. AJNR Am J Neuroradiol. 2017;38:2334–2340.
Kuno H, Garg N, Qureshi M, et al. CT texture analysis of cervical lymph nodes on contrast-enhanced [18F] FDG-PET/CT images to differentiate nodal metastases from reactive lymphadenopathy in HIV-positive patients with head and neck squamous cell carcinoma. AJNR Am J Neuroradiol. 2019;40:543–550.
Seiwert TY, Zuo Z, Keck MK, et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015;21:632–641.
Keck MK, Zuo Z, Khattri A, et al. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res. 2015;21:870–881.
Armato S III. Abras: A Software Tool to Support Observer Studies and Clinical Trials.
Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2015;278:563–577.
Bai HX, Lee AM, Yang L, et al. Imaging genomics in cancer research: limitations and promises. Br J Radiol. 2016;89:20151030. doi:https://doi.org/10.1259/bjr.20151030.
doi: 10.1259/bjr.20151030
Moon SH, Kim J, Joung J-G, et al. Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer. Eur J Nucl Med Mol Imaging. 2019;46:446–454. doi:https://doi.org/10.1007/s00259-018-4138-5.
doi: 10.1007/s00259-018-4138-5
Jaffe CC. Imaging and genomics: is there a synergy? Radiology. 2012;264:329–331.
Lohrisch C, Francl M, Sun S, et al. Willingness of breast cancer patients to undergo biopsy and breast cancer clinicians' practices around seeking biopsy at the time of breast cancer relapse. Breast Cancer Res Treat. 2018;168:221–228.
Lui VWY, Hedberg ML, Li H, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 2013;3:761–769.
Koole K, Brunen D, van Kempen PMW, et al. FGFR1 is a potential prognostic biomarker and therapeutic target in head and neck squamous cell carcinoma. Clin Cancer Res. 2016;22:3884–3893.
SenthilKumar G, Miller M, Fisher M, et al. Abstract 2929: radiosensitization of head and neck cancer by FGFR inhibition. Cancer Res. 2019;79:2929–2929.
Wanebo HJ, Lee J, Burtness BA, et al. Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303). Ann Oncol. 2014;25:2036–2041.
Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381:338–348.
Joerger M, Takahashi S, Sayehli CM, et al. Phase I experience with rogaratinib in patients with head and neck cancer selected based on FGFR mRNA overexpression. Ann Oncol. 2018;29:viii372–vii399.
Lee H-Y, Mohammed KA, Kaye F, et al. EphA2 targeted intratumoral therapy for non-small cell lung cancer using albumin mesospheres. Am J Transl Res. 2017;9:3293–3303.
Cai Y, Dodhia S, Su GH. Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma. Oncotarget. 2017;8:22203–22217.
Parekh V, Jacobs MA. Radiomics: a new application from established techniques. Expert Rev Precis Med Drug Dev. 2016;1:207–226. doi:https://doi.org/10.1080/23808993.2016.1164013.
doi: 10.1080/23808993.2016.1164013
Foy JJ, Robinson KR, Li H, et al. Variation in algorithm implementation across radiomics software. JMI. 2018;5:044505.
Ozkan E, West A, Dedelow JA, et al. CT gray-level texture analysis as a quantitative imaging biomarker of epidermal growth factor receptor mutation status in adenocarcinoma of the lung. Am J Roentgenol. 2015;205:1016–1025.
Becker M. CT texture analysis: defining and integrating new biomarkers for advanced oncologic imaging in precision medicine: a comment on" CT texture analysis potentially predicts local failure in head and neck squamous cell carcinoma treated with Chemoradiotherapy". AJNR Am J Neuroradiol. 2017;38:2341–2343.
Gajewski T, Corrales L, Williams J, et al. Cancer immunotherapy targets based on understanding the T cell-inflamed versus non-T cell-inflamed tumor microenvironment. Adv Exp Med Biol. 2017;1036:19–31.
Ng F, Kozarski R, Ganeshan B, et al. Assessment of tumor heterogeneity by CT texture analysis: can the largest cross-sectional area be used as an alternative to whole tumor analysis? Eur J Radiol. 2013;82:342–348.